Announcements Trials
Browse Landscape

Phase

Phase 2 61Phase 3 25Phase 1 20Phase 1/2 18Phase 2/3 6Phase NA 3

Status

Recruiting 6Not yet recruiting 3Unknown 2Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Breast 1

Conditions

Pancreatic Neoplasms 2Triple Negative Breast Neoplasms 1Lung Neoplasms 1Gallbladder Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Cisplatin 22pembrolizumab 17Drug Therapy 16Carboplatin 15Paclitaxel 12Dexamethasone 12Gemcitabine 11Magnetic Resonance Spectroscopy 10Bevacizumab 10Docetaxel 9venetoclax 8atezolizumab 8Pemetrexed 8Oxaliplatin 8Specimen Handling 7Radiotherapy 7Nivolumab 7Cyclophosphamide 7Capecitabine 7Methotrexate 6130-nm albumin-bound paclitaxel 6durvalumab 5blinatumomab 5Cytarabine 5Androgen Antagonists 5tislelizumab 4spartalizumab 4pertuzumab 4Vincristine 4Trimethoprim, Sulfamethoxazole Drug Combination 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2/3 × Recruiting × 130-nm albumin-bound paclitaxel × Clear all
NCT06926868 2026-05-29

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Bristol-Myers Squibb

Phase 2/3 Recruiting
500 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06361888 2026-05-28

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Hutchmed

Phase 2/3 Recruiting
502 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT07365319 2026-05-20

TeLuRide-008

Eikon Therapeutics

Phase 2/3 Recruiting
750 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07063745 2026-05-18

MountainTAP-29

Bristol-Myers Squibb

Phase 2/3 Recruiting
590 enrolled
Thoracic

Lung Neoplasms

NCT06214572 2025-04-11

RUGB

Tata Memorial Centre

Phase 2/3 Recruiting
249 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms

NCT05254171 2024-11-06

ASPIRE

Panbela Therapeutics, Inc.

Phase 2/3 Recruiting
600 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡